Furthermore, our findings emphasized EGFR mutational status may be relevant for the further conduct and planning of clinical trials investigating the therapeutic value of immune modulatory treatment strategies in glioma patients (Fig. 7K). The gene discussed is EGFR; the disease is central nervous system cancer.